LB
LBTSF.US Almirall S.A
- Market cap
- USD 3.34B
- P/E
- 61.4x
- P/B
- 1.67x
- ROE
- 5.2%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LBTSF.US undervalued?
Graham numberLBTSF.US trades 113.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Almirall S.A fundamental analysis
No fundamental analysis for Almirall S.A yet.
Almirall S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Almirall S.A
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary syst…
Full company profileAlmirall S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Almirall S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 764M | 639M | 757M | 855M | 1.61B | 827M | 863M | 895M | 986M | 1.11B | 1.20B |
| Gross Profit | 602M | 466M | 594M | 663M | 1.44B | 656M | 681M | 682M | 768M | 456M | 1.87B |
| Operating Income | 112M | -310M | 87.0M | 150M | 92.3M | 5.75M | 46.9M | -5.26M | 36.1M | 67.7M | 1.05B |
| EBITDA | 193M | -217M | 171M | 264M | 213M | 124M | 157M | 114M | 174M | 219M | 626M |
| Net Income | 75.5M | -304M | 77.7M | 106M | 74.3M | -40.9M | 4.28M | -38.5M | 10.1M | 46.2M | 79.2M |
| EPS | 0.44 | -1.75 | 0.41 | 0.56 | 0.39 | -0.23 | 0.02 | -0.20 | 0.05 | 0.22 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 2.82B | 2.18B | 2.39B | 2.44B | 2.29B | 2.14B | 2.15B | 2.37B | 2.40B | 2.34B | 2.37B |
| Total Liabilities | 1.30B | 1.04B | 1.20B | 1.16B | 988M | 856M | 829M | 912M | 908M | 829M | 837M |
| Shareholders' Equity | 1.52B | 1.13B | 1.19B | 1.28B | 1.30B | 1.29B | 1.32B | 1.46B | 1.49B | 1.49B | 1.53B |
| Cash & Short-term Investments | 467M | 280M | 86.3M | 117M | 166M | 207M | 249M | 388M | 377M | 339M | 355M |
| Total Debt | 339M | 265M | 535M | 503M | 497M | 396M | 404M | 403M | 409M | 343M | 356M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 105M | 6.09M | 143M | 276M | 165M | 234M | 155M | 93.5M | 161M | 169M | 253M |
| Capital Expenditure | 76.6M | 68.8M | 598M | 135M | 76.5M | 71.2M | 116M | 159M | 161M | 34.9M | 205M |
| Free Cash Flow | 28.4M | -62.7M | -455M | 141M | 88.2M | 163M | 38.6M | -65.8M | -664K | 134M | 59.5M |
| Ratios | |||||||||||
| ROE | 5.0% | -26.8% | 6.5% | 8.3% | 5.7% | -3.2% | 0.3% | -2.6% | 0.7% | 3.1% | 5.2% |
| ROA | 2.7% | -14.0% | 3.3% | 4.3% | 3.2% | -1.9% | 0.2% | -1.6% | 0.4% | 2.0% | 3.3% |
| Net Profit Margin | 9.9% | -47.5% | 10.3% | 12.4% | 4.6% | -4.9% | 0.5% | -4.3% | 1.0% | 4.2% | 6.6% |
| Debt to Equity | 0.22x | 0.23x | 0.45x | 0.39x | 0.38x | 0.31x | 0.31x | 0.28x | 0.27x | 0.23x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Almirall S.A dividends
- Dividend yield
- 1.36%
- Forward dividend
- 0.21 USD
- Payout ratio
- 56.7%
- Ex-dividend date
- May 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 26.2M | 0.12 | 56.7% |
| 2024 | EUR 3.29M | 0.02 | 32.4% |
| 2023 | USD 2.59M | 0.01 | - |
| 2022 | EUR 12.4M | 0.07 | 290.1% |
| 2021 | USD 11.7M | 0.07 | - |
| 2020 | USD 2.13M | 0.01 | 2.9% |
| 2019 | USD 24.1M | 0.13 | 22.8% |
| 2018 | USD 22.7M | 0.12 | 29.2% |
| 2017 | USD 33.0M | 0.19 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 47:46 on Sep 14, 2020.
Who owns Almirall S.A
- Insiders 64.96%
- Institutions 15.90%
- Public & others 19.14%
- Shares outstanding 218M
- Free float 78.3M
Almirall S.A company profile
- Company name
- Almirall S.A
- Ticker
- LBTSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,108
- Fiscal year end
- December
- Address
- Ronda General Mitre, 151, Barcelona, Spain, 08022
- Phone
- 34 93 291 30 00
- Website
- almirall.com
About Almirall S.A
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Almirall S.A management
10- Mr. Carlos Gallardo PiquéCEO, Member of Management Board & Chairman of the Board · born 1972
- Mr. Jon U. Garay AlonsoCFO & Member of Management Board · born 1973
- Mr. Eloi Crespo CerveraChief Industrial Operations Officer & Member of Management Board
- Mr. Esteve Conesa PanicotChief People & Culture Officer and Member of Management Board
- Dr. Volker KoscielnyChief Medical Officer & Member of Management Board
- Dr. Karl ZiegelbauerChief Scientific Officer & Member of Management Board
- Ms. Isabel Cristina GomesCompany Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board
- Mr. Paul RittmanMember of Management Board and President & GM of Almirall US
- Ms. Lidia Martin PeredaChief Commercial Officer of Europe & International and Member of Management Board
- Mr. Pablo Divasson del FraileSenior Director of Investor Relations